NanoDx
NanoDx develops rapid point-of-care medical devices for diagnosing and managing traumatic brain injuries.
Founded
2010NanoDx develops rapid point-of-care medical devices for diagnosing and managing traumatic brain injuries.
NanoDx, founded as a privately held medical device company, focuses on developing innovative and rapid point-of-care technologies for the diagnosis and management of traumatic brain injuries (TBI), including concussions. Their core mission is to provide accurate, real-time diagnostic solutions that can significantly improve patient outcomes. The company's flagship product, the NanoDx™ System, utilizes a unique combination of nanotechnology and biochemistry to deliver precise diagnostic results swiftly, addressing critical unmet needs in medical testing.
Notable figures associated with NanoDx include a team of experts in nanotechnology and biochemistry, though specific names are not provided. The company has attracted significant attention from investors interested in advancing medical diagnostics. Key achievements include the development and deployment of their NanoDx™ System, which has the potential to revolutionize TBI diagnosis by enabling faster and more accurate treatment decisions. Overall, NanoDx is poised to make a substantial impact on the healthcare industry by enhancing the speed and accuracy of medical diagnostics.
Companies similar to NanoDx include BioNanovations, Banyan Biomarkers, Wireless Diagnostic Systems and Nano Mobile Healthcare.
NanoDx was founded in 2010.
NanoDx's headquarters is located in Southborough, MA, US.
NanoDx's most recent funding round was for $18M (USD) in June 2020.
As of Jun 29, 2020, NanoDx has disclosed funding of $37.9M (USD). Undisclosed round amounts are excluded.
NanoDx has 38 employees as of Feb 4, 2024.
Nano Mobile Healthcare
